MedTrace Logo

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

NCT04612673 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-11-03

No results posted yet for this study

Summary

The purpose of this study is to to explore the efficacy and safety of PD-1 immune check point inhibitor, sintilimab, in biomarker-selected subjects with advanced or metastatic Non-small Cell Lung Cancer who have failed from standard front-line treatment.

Conditions

Interventions

DRUG

Sintilimab

immune checkpoint inhibitor, 200mg, iv, d1,Q3W

Sponsors & Collaborators

  • Shengjing Hospital

    collaborator OTHER

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • The People's Hospital of Liaoning Province

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Anshan Tumor Hospital

    collaborator OTHER

  • Benxi Cental Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD · China Medical University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2022-06-30
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612673 on ClinicalTrials.gov